2bind Newsblog

Newsblog

2024

2bind GmbH, a leading contract research organization (CRO) specializing in biophysical analysis for drug discovery and antibody development, today announced a transition in its executive leadership. Dr. Thomas Schubert, Co-CEO, has decided to step down from his role, effective October 31, 2024, to pursue other opportunities and dedicate more time to his family.

2bind GmbH Opens New Headquarters to as a Result of Quality Work and Continued Growth  

2023

2bind GmbH Elevates Dr. Cosimo Kropp to Chief Business Officer  

2bind GmbH Launches Antibody Unit with Appointment of Dr. Vera Molkenthin as Director  

2021

2bind GmbH Strengthens Business Development with Appointment of Dr. Cosimo Kropp  

A collaborative research project based in Regensburg is leveraging cutting-edge technology and expertise to develop a novel drug against COVID-19. The project unites 2bind GmbH, a leading biophysical analysis company located in BioPark Regensburg, with researchers from the University of Regensburg and the Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM).

The federally funded interdisciplinary research project “HIVacToGC” was launched to investigate new approaches to the prevention and treatment of HIV infections.

2019

2bind wins first place in the EU's Eureka Eurostars competition, together with partners from the Netherlands and Great Britain.

2bind GmbH Appoints Dr. Maximilian Plach as COO to Oversee Rapid Growth  

2018

2bind GmbH and Assay.Works Join Forces to Expand Drug Discovery Services  

2017

2bind GmbH Appoints Dr. Maximilian Plach as CSO to Drive Biophysics in Drug Discovery 

2bind GmbH Appoints Dr. Thomas Schubert as CEO to Lead Strategic Shift Towards Drug Discovery Research Services  .

2bind GmbH Relaunches with Renewed Focus on Empowering Drug Discovery through Biophysical Research Services.

Did You Know?

As scientist we understand that successful research requires a clear but also flexible approach. Our quotations, project and reports reflect this need with a fine-grained milestone architecture with multiple stop criteria and exit options.

Work with the experts in biophysics!

Im Gewerbepark D19a
93059 Regensburg

+49 941 2000 0890
info@2bind.com